Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
about
A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.The Putative Role of Environmental Mercury in the Pathogenesis and Pathophysiology of Autism Spectrum Disorders and Subtypes.Dose site reactions and related findings after vaccine administration in safety studies.Calcium phosphate: a substitute for aluminum adjuvants?An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.The Hen's Egg Test on Chorioallantoic Membrane: An Alternative Assay for the Assessment of the Irritating Effect of Vaccine Adjuvants.Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial.Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils.Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.The Positive Correlation of the Enhanced Immune Response to PCV2 Subunit Vaccine by Conjugation of Chitosan Oligosaccharide with the Deacetylation Degree.The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of three protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control.Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human Antibodies.Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases.Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral VectorsVaccines for preventing hepatitis B in healthcare workers (an updated protocol)The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted VaccinationQuillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses
P2860
Q36240389-0B6A1A5F-0352-4533-97A3-11DD9E295AE4Q38653427-A63EF4D4-1C8D-4153-9350-324EB0C77A0CQ38770307-B2D9CA7C-BCEF-4558-88D4-674E70E7B0DFQ38969062-FD5662F2-7FDD-4089-8BDC-F6857EC60D50Q39174792-10A0CFF8-1868-4704-9830-C374D9A04647Q39298187-FAD95E4C-9544-46F8-B117-E6702C14FADEQ40069663-486B31A8-F091-48A5-BACF-470CF63A1F88Q40076042-D91B2BD8-66DB-4C2C-B726-5A0ADFC7C56BQ41147045-95193D2D-2FFE-43E5-BD07-83526899985EQ41569795-4F7FD320-7F6E-4D61-90AA-DFE3721ACB53Q41689625-AFD01619-1FC5-45B7-943E-64962070DF80Q41995267-28917B96-B3EE-4074-9564-AA811CB6815DQ45074067-F7530DDC-B02B-4901-8909-1EBFCFC1F621Q47587998-8CA58DD8-4D27-486B-9F16-B6363539E227Q47699178-16F629EC-F0E4-44FB-AD01-49E05ECA9E38Q51732398-8DEA349C-64E5-495A-846A-D38C23968EE0Q52394368-729CB73C-FE1E-4D57-A910-A8E283AA542BQ52643675-9E7D5A6F-CBB5-4E25-A8B5-6FC43E7F8930Q55693712-89246043-9BAB-42D7-BD1F-7CBE1A849DCCQ56341814-C0827B27-9349-4749-8A42-4E24A3C3EC7BQ57389440-EC7EEC5D-7522-420B-9A6F-560DC845DEF8Q57490842-6A0B9E86-1394-4BC8-83DA-992CB460BE81Q58751640-C54677A8-A23B-4F8D-8DAA-1691000CDE65
P2860
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@ast
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@en
type
label
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@ast
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@en
prefLabel
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@ast
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@en
P2860
P1433
P1476
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
@en
P2860
P2888
P304
P356
10.1007/S40264-015-0350-4
P577
2015-10-08T00:00:00Z